Trial Profile

Phase 3 study of CNM Au 8 for Amyotrophic lateral sclerosis

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 28 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CNM Au8 (Primary)
Indications Amyotrophic lateral sclerosis
Focus Therapeutic Use

Most Recent Events

28 Jun 2023 New trial record
21 Jun 2023 The Clene Nanomedicine media release, the company announces closing of underwritten public offering of $40 Million and the company is utilizing the capital raised in this offering to accelerate regulatory discussions and submissions with the FDA together with planning and preparation for commencing this trial.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com